Colorectal polyps and carcinoma

Role of the pathologist

Nilesh Kashikar, Monica Garcia-Buitrago

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Colorectal carcinoma is the third most common cancer in the United States in both men and women, and subsequently it is also the third leading cause of cancer-related death in the United States. In the era of personalized medicine, gastroenterologists, colorectal surgeons, oncologists and medical geneticists have started depending on the pathologist’s consultation in the management of patients with colorectal polyps or carcinoma. The pathologist’s role is not restricted to mere histomorphologic subtyping but is greatly expanding to provide accurate pathologic stage, analysis of surgical resection margins, identification of prognostic parameters that are not included in the staging such as lymph-vascular and perineural invasion, tumor budding, and assessment of therapeutic effect in patients who have received neoadjuvant therapy. With the rapid therapeutic advancement in available therapeutic options, pathologists also play a leading role in assessing mismatch repair protein expression, selecting appropriate tissue sections for microsatellite instability testing and KRAS, NRAS, BRAF, and PIK3CA mutation analysis, and in interpreting the results of these important therapeutic and prognostic tests. This chapter focuses in the role of the pathologist evaluating preneoplastic lesions, malignant polyps and familial polyposis as well as colorectal carcinoma and its predictor and prognostic factors.

Original languageEnglish (US)
Title of host publicationGastrointestinal Cancers
Subtitle of host publicationPrevention, Detection and Treatment
PublisherNova Science Publishers, Inc.
Pages1-40
Number of pages40
Volume2
ISBN (Electronic)9781536101799
ISBN (Print)9781536101690
StatePublished - Jan 1 2016

Fingerprint

Polyps
Colorectal Neoplasms
Neoplasms
Microsatellite Instability
Precision Medicine
DNA Mismatch Repair
Neoadjuvant Therapy
Lymph
Therapeutic Uses
Blood Vessels
Therapeutics
Referral and Consultation
Carcinoma
Mutation
Pathologists
Proteins
Margins of Excision

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Kashikar, N., & Garcia-Buitrago, M. (2016). Colorectal polyps and carcinoma: Role of the pathologist. In Gastrointestinal Cancers: Prevention, Detection and Treatment (Vol. 2, pp. 1-40). Nova Science Publishers, Inc..

Colorectal polyps and carcinoma : Role of the pathologist. / Kashikar, Nilesh; Garcia-Buitrago, Monica.

Gastrointestinal Cancers: Prevention, Detection and Treatment. Vol. 2 Nova Science Publishers, Inc., 2016. p. 1-40.

Research output: Chapter in Book/Report/Conference proceedingChapter

Kashikar, N & Garcia-Buitrago, M 2016, Colorectal polyps and carcinoma: Role of the pathologist. in Gastrointestinal Cancers: Prevention, Detection and Treatment. vol. 2, Nova Science Publishers, Inc., pp. 1-40.
Kashikar N, Garcia-Buitrago M. Colorectal polyps and carcinoma: Role of the pathologist. In Gastrointestinal Cancers: Prevention, Detection and Treatment. Vol. 2. Nova Science Publishers, Inc. 2016. p. 1-40
Kashikar, Nilesh ; Garcia-Buitrago, Monica. / Colorectal polyps and carcinoma : Role of the pathologist. Gastrointestinal Cancers: Prevention, Detection and Treatment. Vol. 2 Nova Science Publishers, Inc., 2016. pp. 1-40
@inbook{1b884da7779a4c57b4a1851c97e93247,
title = "Colorectal polyps and carcinoma: Role of the pathologist",
abstract = "Colorectal carcinoma is the third most common cancer in the United States in both men and women, and subsequently it is also the third leading cause of cancer-related death in the United States. In the era of personalized medicine, gastroenterologists, colorectal surgeons, oncologists and medical geneticists have started depending on the pathologist’s consultation in the management of patients with colorectal polyps or carcinoma. The pathologist’s role is not restricted to mere histomorphologic subtyping but is greatly expanding to provide accurate pathologic stage, analysis of surgical resection margins, identification of prognostic parameters that are not included in the staging such as lymph-vascular and perineural invasion, tumor budding, and assessment of therapeutic effect in patients who have received neoadjuvant therapy. With the rapid therapeutic advancement in available therapeutic options, pathologists also play a leading role in assessing mismatch repair protein expression, selecting appropriate tissue sections for microsatellite instability testing and KRAS, NRAS, BRAF, and PIK3CA mutation analysis, and in interpreting the results of these important therapeutic and prognostic tests. This chapter focuses in the role of the pathologist evaluating preneoplastic lesions, malignant polyps and familial polyposis as well as colorectal carcinoma and its predictor and prognostic factors.",
author = "Nilesh Kashikar and Monica Garcia-Buitrago",
year = "2016",
month = "1",
day = "1",
language = "English (US)",
isbn = "9781536101690",
volume = "2",
pages = "1--40",
booktitle = "Gastrointestinal Cancers",
publisher = "Nova Science Publishers, Inc.",

}

TY - CHAP

T1 - Colorectal polyps and carcinoma

T2 - Role of the pathologist

AU - Kashikar, Nilesh

AU - Garcia-Buitrago, Monica

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Colorectal carcinoma is the third most common cancer in the United States in both men and women, and subsequently it is also the third leading cause of cancer-related death in the United States. In the era of personalized medicine, gastroenterologists, colorectal surgeons, oncologists and medical geneticists have started depending on the pathologist’s consultation in the management of patients with colorectal polyps or carcinoma. The pathologist’s role is not restricted to mere histomorphologic subtyping but is greatly expanding to provide accurate pathologic stage, analysis of surgical resection margins, identification of prognostic parameters that are not included in the staging such as lymph-vascular and perineural invasion, tumor budding, and assessment of therapeutic effect in patients who have received neoadjuvant therapy. With the rapid therapeutic advancement in available therapeutic options, pathologists also play a leading role in assessing mismatch repair protein expression, selecting appropriate tissue sections for microsatellite instability testing and KRAS, NRAS, BRAF, and PIK3CA mutation analysis, and in interpreting the results of these important therapeutic and prognostic tests. This chapter focuses in the role of the pathologist evaluating preneoplastic lesions, malignant polyps and familial polyposis as well as colorectal carcinoma and its predictor and prognostic factors.

AB - Colorectal carcinoma is the third most common cancer in the United States in both men and women, and subsequently it is also the third leading cause of cancer-related death in the United States. In the era of personalized medicine, gastroenterologists, colorectal surgeons, oncologists and medical geneticists have started depending on the pathologist’s consultation in the management of patients with colorectal polyps or carcinoma. The pathologist’s role is not restricted to mere histomorphologic subtyping but is greatly expanding to provide accurate pathologic stage, analysis of surgical resection margins, identification of prognostic parameters that are not included in the staging such as lymph-vascular and perineural invasion, tumor budding, and assessment of therapeutic effect in patients who have received neoadjuvant therapy. With the rapid therapeutic advancement in available therapeutic options, pathologists also play a leading role in assessing mismatch repair protein expression, selecting appropriate tissue sections for microsatellite instability testing and KRAS, NRAS, BRAF, and PIK3CA mutation analysis, and in interpreting the results of these important therapeutic and prognostic tests. This chapter focuses in the role of the pathologist evaluating preneoplastic lesions, malignant polyps and familial polyposis as well as colorectal carcinoma and its predictor and prognostic factors.

UR - http://www.scopus.com/inward/record.url?scp=85029915098&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029915098&partnerID=8YFLogxK

M3 - Chapter

SN - 9781536101690

VL - 2

SP - 1

EP - 40

BT - Gastrointestinal Cancers

PB - Nova Science Publishers, Inc.

ER -